Valuation: Solid Biosciences Inc.

Market Cap 685M 614M 566M 512M 958M 65.25B 974M 6.75B 2.69B 34.15B 2.57B 2.52B 108B P/E 2026 *
-3.69x
P/E 2027 * -3.79x
Enterprise Value 392M 351M 324M 293M 548M 37.34B 557M 3.87B 1.54B 19.54B 1.47B 1.44B 61.9B EV / Sales 2026 *
-
EV / Sales 2027 * 49.1x
Free-Float
88.21%
Yield 2026 *
-
Yield 2027 * -
1 day-1.39%
1 week+3.23%
Current month-11.62%
1 month-10.75%
3 months-20.52%
6 months-9.36%
Current year+13.30%
1 week 5.74
Extreme 5.74
6.65
1 month 5.38
Extreme 5.385
7.26
Current year 4.92
Extreme 4.92
11.45
1 year 3.79
Extreme 3.79
11.45
3 years 2
Extreme 2
15.05
5 years 1.81
Extreme 1.81
37.65
10 years 1.81
Extreme 1.81
822.6
Manager TitleAgeSince
Chief Executive Officer 55 2022-12-01
Corporate Officer/Principal - 2014-08-31
Director of Finance/CFO 48 2023-01-08
Director TitleAgeSince
Director/Board Member 52 2013-02-28
Director/Board Member 60 2015-10-31
Director/Board Member 46 2015-10-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/2/26 Exercice

Chairman

6,880 0.0064%
7/2/26 Exercice

Chairman

6,880 0.0070%
6/10/26 Free

Founder

77,500 0.0787%
Change 5-day change 1-year change 3-year change Capi.($)
-1.39%+3.23%+16.39%+238.10% 685M
+0.34%+1.12%+34.75%+61.06% 64.38B
-0.17%+2.66%+14.32%+83.58% 56.16B
+1.06%+2.50%+15.97%+107.90% 54.16B
-1.43%-1.17%+26.27%+52.86% 45.33B
-0.48%-2.80%+18.01%+117.99% 42.25B
+0.82%+1.37%+227.94%+922.41% 40.78B
+0.82%+44.36%+107.50%+91.71% 33.8B
-0.26%-2.57%+12.55%+45.18% 32.25B
-1.29%-2.88%+21.60%-11.92% 23.57B
Average -0.19%+4.37%+49.53%+170.89% 39.34B
Weighted average by Cap. +0.02%+3.60%+50.11%+162.46%

Financials

2026 *2027 *
Net sales - 8.59M 7.7M 7.1M 6.43M 12.02M 818M 12.21M 84.73M 33.8M 428M 32.26M 31.57M 1.36B
Net income -226M -202M -186M -169M -315M -21.48B -321M -2.22B -887M -11.24B -847M -829M -35.61B -243M -217M -201M -181M -339M -23.11B -345M -2.39B -955M -12.1B -911M -891M -38.31B
Net Debt -293M -262M -242M -219M -410M -27.9B -416M -2.89B -1.15B -14.6B -1.1B -1.08B -46.25B -263M -236M -218M -197M -368M -25.08B -374M -2.6B -1.04B -13.12B -988M -967M -41.57B
Projected Income Statement - Annual - Solid Biosciences Inc.
Logo Solid Biosciences Inc.
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Employees
121
Date Price Change Volume
26-10-29 US$6.390 -1.39% 964,670
26-10-28 US$6.480 +4.68% 1,510,804
26-10-27 US$6.190 +6.54% 1,551,485
26-10-26 US$5.810 -1.86% 1,070,934
26-10-23 US$5.920 -4.36% 769,967
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Solid Biosciences Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
6.390USD
Average target price
18.71USD
Spread / Average Target
+192.87%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Solid Biosciences Inc.
  1. Stock Market
  2. Stocks
  3. SLDB Stock